priors.science/reviews/lipid-management-cardiovascular-risk

Lipid Management Cardiovascular Risk

The current evidence on 18 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

18claims tracked
Weeklyre-scored against new papers
6 Established · 12 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableRNA interference reduces lipoprotein(a) levelsNovel Lipid AgentsEstablished89%10
StableBempedoic acid for statin-intolerant patientsNovel Lipid AgentsEstablished89%10
StableElevated lipoprotein(a) predicts cardiovascular eventsResidual Lipid RiskEstablished87%10
StableStatins reduce major cardiovascular eventsStatin TherapyEstablished87%10
StableStatins in primary preventionStatin TherapyEstablished86%10
StableEarly PCSK9 inhibitor timing after acute coronary syndromePcsk9 InhibitorsEstablished85%4
StableNon-high-density lipoprotein cholesterol residual risk beyond low-density lipoprotein cholesterolResidual Lipid RiskLikely84%10
StableLow-density lipoprotein cholesterol targets underachieved in practiceLDL TargetsLikely84%8
StablePCSK9 inhibitors reduce major adverse cardiovascular events in atherosclerotic cardiovascular diseasePcsk9 InhibitorsLikely83%10
StableApolipoprotein B versus low-density lipoprotein cholesterol for atherosclerotic cardiovascular disease predictionResidual Lipid RiskLikely82%10
StableStatin plus ezetimibe versus high-intensity statinCombination TherapyLikely81%7
StableInclisiran biannual low-density lipoprotein cholesterol loweringPcsk9 InhibitorsLikely81%10
StablePCSK9 inhibitors lower lipoprotein(a) and low-density lipoprotein cholesterolNovel Lipid AgentsLikely80%10
StableRemnant cholesterol predicts residual cardiovascular disease riskResidual Lipid RiskLikely79%10
StableHigh-intensity statin major adverse cardiovascular event benefitStatin TherapyLikely79%10
StableEzetimibe plus statin versus statin aloneCombination TherapyLikely74%10
StableLow-density lipoprotein cholesterol 55 versus 70 mg/dL targetLDL TargetsLikely71%7
StableEarly ezetimibe after myocardial infarction benefitCombination TherapyLikely65%10
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic